Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2021Yazar
Yigenoğlu, Tuğçe NurBaşçı, Semih
Şahin, Derya
Ulaş, Turgay
Dal, Mehmet Sinan
Korkmaz, Serdal
Altuntaş, Fevzi
Turgut, Burhan
Üst veri
Tüm öğe kaydını gösterÖzet
SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.